Development of liposomal ginsenoside Rg3: Formulation optimization and evaluation of its anticancer effects

International Journal of Pharmaceutics

Volumn 450, Issue 1-2, 2013, Pages 250-258

  Yu, Huan ^a   Teng, Lirong ^a   Meng, Qingfan ^a   Li, Yuhuan ^a   Sun, Xiaocheng ^a   Lu, Jiahui ^a   J Lee, Robert ^a,b   Teng, Lesheng ^a,b  

^a JILIN UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Antitumor activity; Cytotoxicity; Ginsenoside Rg3; Liposome

Indexed keywords

CD34 ANTIGEN; GINSENOSIDE RG 3; GINSENOSIDE RH 2; LIPOSOME; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CAPILLARY DENSITY; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; LUNG ADENOCARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MICROENCAPSULATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; RESPONSE SURFACE METHOD; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; FEMALE; GINSENOSIDES; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; NEOPLASMS; PHOSPHATIDYLCHOLINES; RATS; RATS, WISTAR; TUMOR BURDEN;

EID: 84878349416     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.065     Document Type: Article

References (45)

1. R. Abe, Y. Fujita, and S. Yamagishi Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma Mini Rev. Med. Chem. 7 2007 649 661
2. D. Andes Clinical utility of antifungal pharmacokinetics and pharmacodynamics Curr. Opin. Infect. Dis. 17 2004 533 540
3. A.S. Attele, J.A. Wu, and C.S. Yuan Ginseng pharmacology: multiple constituents and multiple actions Biochem. Pharmacol. 58 1999 1685 1693
4. G. Bergers, and L.E. Benjamin Tumorigenesis and the angiogenic switch Nat. Rev. Cancer 3 2003 401 410
5. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
6. J. Chen, H. Peng, X. Ou-Yang, and X. He Research on the antitumor effect of Ginsenoside Rg3 in B16 melanoma cells Melanoma Res. 18 2008 322 329
7. W.D. Chiang, S.W. Chang, and C.J. Shieh Studies on the optimized lipase-catalyzed biosynthesis of cis-3-hexen-l-yl acetate in n-hexane Process Biochem. 38 2003 1193 1199
8. J. Folkman Tumor angiogenesis: therapeutic implications New Engl. J. Med. 285 1971 1182 1186
9. J. Folkman What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82 1990 4 6
10. J. Folkman The role of angiogenesis in tumor growth Semin. Cancer Biol. 3 1992 65 71
11. R.L. Foote, N. Weidner, J. Harris, E. Hammond, J.E. Lewis, T. Vuong, K.K. Ang, and K.K. Fu Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505 Int. J. Radiat. Oncol. Biol. Phys. 61 2005 745 753
12. D.R. Hamsaveni, S.G. Prapulla, and S. Divakar Response surface methodological approach for the synthesis of isobutyl isobutyrate Process Biochem. 36 2001 1103 1109
13. N. Hatambeygi, G. Abedi, and M. Talebi Method development and validation for optimised separation of salicylic, acetyl salicylic and ascorbic acid in pharmaceutical formulations by hydrophilic interaction chromatography and response surface methodology J. Chromatogr. A 1218 2011 5995 6003
14. J.Y. Huang, Y. Sun, Q.X. Fan, and Y.Q. Zhang Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: a randomized controlled trial Zhong xi yi jie he xue bao = J. Chinese Integr. Med. 7 2009 1047 1051
15. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat. Med. 7 2001 987 989
16. D. Kiefer, and T. Pantuso Panax ginseng Am. Fam. Physician 68 2003 1539 1542
17. H.S. Kim, E.H. Lee, S.R. Ko, K.J. Choi, J.H. Park, and D.S. Im Effects of Ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells Arch. Pharm. Res. 27 2004 429 435
18. N.V. Koshkina, J.C. Waldrep, L.E. Roberts, E. Golunski, S. Melton, and V. Knight Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 7 2001 3258 3262
19. S.S. Lakka, and J.S. Rao Antiangiogenic therapy in brain tumors Expert Rev. Neurother. 8 2008 1457 1473
20. T.K. Lee, R.M. Johnke, R.R. Allison, K.F. O'Brien, and L.J. Dobbs Jr. Radioprotective potential of ginseng Mutagenesis 20 2005 237 243
21. C. Li, Y. Deng, and J. Cui Preparation of liposomes adn oily formulations by freeze-drying of monophase solutions 3rd Ed G. Gregoriadis, Liposome Technology vol I 2006 Informa Healthcare 35 53
22. H. Li, J. Wang, Y.F. Guan, W.J. Yang, A.Y. Aiying Suo, M.H. Chu, C.Y. Wang, J. Jiang, S.P. Zhai, and Q.S. Mao Synergistic effects of Ginsenoside Rg3 and cyclophosphamine on tumor growth and angiogenesis in lung cancer Afr. J. Biotechnol. 10 2011 10040 10044
23. C.-b. Liu, D. Zhang, D.-g. Li, D. Jiang, and X. Chen Preparation and characterization of biodegradable polylactide (PLA) microspheres encapsulating Ginsenoside Rg3 Chem. Res. Chinese Univ. 24 2008 588 591
24. P. Lu, W. Su, Z.H. Miao, H.R. Niu, J. Liu, and Q.L. Hua Effect and mechanism of Ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer Chinese J. Integr. Med. 14 2008 33 36
25. X. Luo, C.Z. Wang, J. Chen, W.X. Song, J. Luo, N. Tang, B.C. He, Q. Kang, Y. Wang, W. Du, T.C. He, and C.S. Yuan Characterization of gene expression regulated by American ginseng and Ginsenoside Rg3 in human colorectal cancer cells Int. J. Oncol. 32 2008 975 983
26. H. Maeda, J. Fang, T. Inutsuka, and Y. Kitamoto Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications Int. Immunopharmacol. 3 2003 319 328
27. D.E. Mager, S. Woo, and W.J. Jusko Scaling pharmacodynamics from in vitro and preclinical animal studies to humans Drug Metab. Pharmacokinet. 24 2009 16 24
28. C. Magnon, A. Galaup, V. Rouffiac, P. Opolon, E. Connault, M. Rose, M. Perricaudet, A. Roche, S. Germain, F. Griscelli, and N. Lassau Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration Gene Ther. 14 2007 108 117
29. Y. Omokawa, T. Miyazaki, P. Walde, K. Akiyama, T. Sugahara, S. Masuda, A. Inada, Y. Ohnishi, T. Saeki, and K. Kato In vitro and in vivo anti-tumor effects of novel Span 80 vesicles containing immobilized Eucheuma serra agglutinin Int. J. Pharm. 389 2010 157 167
30. B. Shpitz, S. Gochberg, D. Neufeld, M. Grankin, G. Buklan, E. Klein, and J. Bernheim Angiogenic switch in earliest stages of human colonic tumorigenesis Anticancer Res. 23 2003 5153 5157
31. W. Tang, Y. Zhang, J. Gao, X. Ding, and S. Gao The anti-fatigue effect of 20(R)-Ginsenoside Rg3 in mice by intranasally administration Biol. Pharm. Bull. 31 2008 2024 2027
32. H. Wang, H. Zou, L. Kong, Y. Zhang, H. Pang, C. Su, G. Liu, M. Hui, and L. Fu Determination of Ginsenoside Rg3 in plasma by solid-phase extraction and high-performance liquid chromatography for pharmacokinetic study J. Chromatogr. B: Biomed. Sci. Appl. 731 1999 403 409
33. Y. Wang, Y. Jin, C. Zhou, H. Qu, and Y. Cheng Discovering active compounds from mixture of natural products by data mining approach Med. Biol. Eng. Comput. 46 2008 605 611
34. J. Wu, Q. Liu, and R.J. Lee A folate receptor-targeted liposomal formulation for paclitaxel Int. J. Pharm. 316 2006 148 153
35. Y. Xiong, D. Guo, L. Wang, X. Zheng, Y. Zhang, and J. Chen Development of nobiliside A loaded liposomal formulation using response surface methodology Int. J. Pharm. 371 2009 197 203
36. T.M. Xu, M.H. Cui, Y. Xin, L.P. Gu, X. Jiang, M.M. Su, D.D. Wang, and W.J. Wang Inhibitory effect of Ginsenoside Rg3 on ovarian cancer metastasis Chinese Med. J. (Engl.) 121 2008 1394 1397
37. T.M. Xu, Y. Xin, M.H. Cui, X. Jiang, and L.P. Gu Inhibitory effect of Ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer Chinese Med. J. (Engl.) 120 2007 584 588
38. S. Yang, J. Chen, D. Zhao, D. Han, and X. Chen Comparative study on preparative methods of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation efficiency Int. J. Pharm. 434 2012 155 160
39. C.S. Yuan, J.A. Wu, and J. Osinski Ginsenoside variability in American ginseng samples Am. J. Clin. Nutr. 75 2002 600 601
40. P.Y. Yue, D.Y. Wong, P.K. Wu, P.Y. Leung, N.K. Mak, H.W. Yeung, L. Liu, Z. Cai, Z.H. Jiang, T.P. Fan, and R.N. Wong The angiosuppressive effects of 20(R)-Ginsenoside Rg3 Biochem. Pharmacol. 72 2006 437 445
41. G. Zhai, J. Wu, X. Zhao, B. Yu, H. Li, Y. Lu, W. Ye, Y.C. Lin, and R.J. Lee A liposomal delivery vehicle for the anticancer agent gossypol Anticancer Res. 28 2008 2801 2805
42. J.A. Zhang, G. Anyarambhatla, L. Ma, S. Ugwu, T. Xuan, T. Sardone, and I. Ahmad Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinsch. Pharm. Verfahrenstech. e. V 59 2005 177 187
43. Q. Zhang, X. Kang, B. Yang, J. Wang, and F. Yang Antiangiogenic effect of capecitabine combined with Ginsenoside Rg3 on breast cancer in mice Cancer Biother. Radiopharm. 23 2008 647 653
44. Z.-S. Zhang, D. Li, L.-J. Wang, N. Ozkan, X.D. Chen, Z.-H. Mao, and H.-Z. Yang Optimization of ethanol-water extraction of lignans from flaxseed Sep. Purif. Technol. 57 2007 17 24
45. C. Zhou, Y. Zhang, B. Yu, M.A. Phelps, L.J. Lee, and R.J. Lee Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes Nanomedicine: nanotechnology, biology, and medicine 9 2013 504 513